Instituto Rosenbusch's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 52.46.
Instituto Rosenbusch's Days Inventory for the
three
months ended in Dec. 2025 was 135.82.
Instituto Rosenbusch's Days Payable for the
three
months ended in Dec. 2025 was 39.43.
Therefore, Instituto Rosenbusch's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 148.85.
Instituto Rosenbusch (BUE:ROSE) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Instituto Rosenbusch Cash Conversion Cycle Related Terms
Instituto Rosenbusch Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Cash Conversion Cycle falls into.
Instituto Rosenbusch Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Instituto Rosenbusch's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Cash Conversion Cycle of 148.85 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Cash Conversion Cycle too high?
Instituto Rosenbusch's current Cash Conversion Cycle is 148.85. The Drug Manufacturers industry median Cash Conversion Cycle is 146.14. Instituto Rosenbusch's value of 148.85 is 1.9% above this industry median. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Cash Conversion Cycle compare to ZTS and UTHR?
Instituto Rosenbusch's Cash Conversion Cycle of 148.85 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 146.14. Instituto Rosenbusch's value of 148.85 is 1.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 146.14, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current Cash Conversion Cycle of 148.85 is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 146.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Cash Conversion Cycle is 148.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.93, compared to a current price of ARS158.00 — trading 155.1% above its estimated fair value. The current Cash Conversion Cycle is 148.85 and 1.9% above the Drug Manufacturers industry median of 146.14. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Cash Conversion Cycle is 148.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS158.00 is trading 155.1% above its estimated GF Value™ of ARS61.93.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Cash Conversion Cycle: 148.85
GF Value™: ARS61.93 vs. price of ARS158.00 (155.1% above fair value)
Industry Position: 1.9% above the Drug Manufacturers median
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
